...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands)
【24h】

Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands)

机译：在阿姆斯特丹（荷兰）为少数民族儿童进行的针对性甲型肝炎疫苗的药物经济评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Estimate cost-effectiveness of vaccination against hepatitis A virus (HAV) for children of ethnic minorities in Amsterdam. Background: Pharmaco-economic analysis is relevant for motivating reimbursement of vaccination costs in the framework of a programmatic approach to vaccination of ethnic minorities. Design: Pharmaco-economic modeling. Method: In cost-effectiveness analysis, costs, benefits and health gains were estimated for a large-scale HAV-vaccination for children of Turkish and Maroccan origin. Analysis was performed from the societal perspective, as recommended in the Dutch guidelines for pharmaco-economic research. This implies that indirect costs of production losses are included in the analysis. Cost-effectiveness was expressed in net costs per adult HAV-infection averted in incremental and aggregate analysis. Incremental analysis compares targeted vaccination with the current limited-scale HAV-vaccination that exists, whereas aggregate analysis compares targeted vaccination with the sheer absence of vaccination. Results: Net aggregate costs of targeted HAV-vaccination for Turkish and Maroccan children in Amsterdam amounts to E 61.000. Cost-effectiveness was estimated, in aggregate and incremental analysis, at E 13.500 and 11.100 respectively per adult HAV-infection averted. Uni- and multivariate sensitivity analyses show that major impact on cost-effectiveness may be expected from reductions in the vaccine price through economies of scale. Probabilistic sensitivity analysis indicates possible large fluctuations in cost-effectiveness from I year to another, related to varying incidence of disease. Conclusion: HAV-vaccination for children from ethnic minorities in Amsterdam is not cost saving, but may have a favourable cost-effectiveness. Such a vaccination program fits into the recent Dutch policy of specific vaccinations directed at groups of ethnic minorities, such as for hepatitis B
机译：目的：估计阿姆斯特丹少数民族儿童接种甲型肝炎病毒（HAV）疫苗的成本效益。背景：药物经济学分析与在计划化的少数民族疫苗接种方法框架内激发疫苗接种费用的返还有关。设计：药物经济学模型。方法：在成本效益分析中，估算了针对土耳其和摩洛哥血统儿童的大规模HAV疫苗接种的成本，收益和健康收益。按照荷兰的药物经济学研究指南的建议，从社会角度进行了分析。这意味着分析中包括了生产损失的间接成本。成本效益用在增量和总体分析中避免的每位成人HAV感染的净成本表示。增量分析将目标疫苗接种与当前存在的限量HAV疫苗进行比较，而汇总分析将目标疫苗接种与完全没有疫苗接种进行比较。结果：在阿姆斯特丹，针对土耳其和摩洛哥儿童的目标HAV疫苗接种的总费用净额为E 61.000。总体而言和逐步增加的分析中，每位避免感染成人的HAV感染的成本效益分别为13.500和11.100。单变量和多变量敏感性分析表明，可以通过规模经济来降低疫苗价格，从而对成本效益产生重大影响。概率敏感性分析表明，从一年到另一年，成本效益可能存在较大的波动，这与疾病的发病率有关。结论：阿姆斯特丹少数民族儿童的甲肝疫苗接种不能节省成本，但可能具有良好的成本效益。这种疫苗接种计划符合荷兰最近针对少数群体（例如乙肝）的特定疫苗接种政策

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号